Chief Scientific Officer
Dr. Springman joined Celtaxsys in 2009 from Locus Pharmaceuticals, where he held several positions of increasing responsibility including Head of Discovery and Technologies and Head of Development. At Locus, he was instrumental in building core technologies as well as discovering and developing 3 clinical candidate compounds resulting in over $50M in partnerships and $30M in venture funding. Additionally, Dr Springman obtained over $3M in public and private grant funding for research and served as an NIH SBIR grant reviewer. In 2007, Dr Springman was appointed by Gov. Edward Rendell to serve on the Pennsylvania Drug, Device and Cosmetics Board for which he served 4 years. Prior to Locus, Dr Springman served as Head of the Arthritis and Fibrosis Therapy Area at Roche Pharmaceuticals and Group Leader at Arris/Axys Pharmaceuticals. Dr Springman received his PhD in Molecular Biophysics from Florida State University and conducted his postdoctoral studies at Vanderbilt University School of Medicine, where he was an American Lung Association Fellow and NIH NRSA Postdoctoral Fellow. He was accepted into the American Academy of Allergy, Asthma and Immunology in 1993.